March 13, 2019
New preclinical data from University of California San Diego School of Medicine and Moores Cancer Center offers proof-of-principle for a combination immunotherapy that suppresses tumor growth in the liver. Current therapies for liver cancer are largely ineffective, resulting in poor outcomes.
July 20, 2017
…Diego School of Medicine researchers to develop a new immunotherapy in which patients’ cells would be equipped with a special receptor that recognizes and targets cancer stem cells, whose survival abilities often render standard therapies ineffective or short-term.
April 22, 2015
San Diego community members, physicians and cancer survivors will come together Saturday, April 25 at the Grand Del Mar for SPARK Gala, an evening to “ignite the fight against cancer.”
March 11, 2024
UC San Diego Health provides the most advanced neurological cancer care by combining leading-edge surgical techniques and the latest technology.
December 4, 2018
In lab and mouse experiments, UC San Diego School of Medicine researchers developed a method to leverage B cells to manufacture and secrete tumor-suppressing microRNAs.
March 27, 2023
Researchers at UC San Diego School of Medicine and Moores Cancer Center at UC San Diego Health examined a new treatment approach for endometrial cancer.
April 12, 2016
To rally the San Diego region in the fight against cancer, the University of California San Diego’s Moores Cancer Center will host its annual SPARK Gala on Saturday, April 16 at the Fairmont Grand Del Mar. The evening will include a three-course dinner with wine pairings, a live luxury auction…
August 12, 2021
A new cancer immunotherapy pairs ultrasound with cancer-killing immune cells to destroy malignant tumors while sparing normal tissue. The approach could make chimeric antigen receptor (CAR) T-cell therapy safer and effective at treating solid tumors.
November 30, 2018
A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy.
April 29, 2015
Researchers at the University of California, San Diego School of Medicine report that blocking or removing immune-suppressing cells allows a special type of chemotherapy — and the immune cells it activates — to destroy prostate tumors. This novel combination therapy, termed chemoimmunotherapy, achieved near complete remission in mouse models of…
